BioPharmSignal logoBioPharmSignal

Biotech News

Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026

Annexon, Inc. (ANNX)Annexon, Inc.Clinical readout

Tanruprubart MAA Filed with Potential to Be the First Targeted Fast-Acting Therapy for Guillain-Barré Syndrome ( GBS); BLA Submission with U.S./European Data Planned in 2026 Vonaprument Pivotal Phase 3 Topline Data for Dry AMD with Geographic Atrophy (GA) on Track for Second Half of 2026

Related news

ANNXAnnexon, Inc.2026-08-12 10:00 EST

Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study

ANNXAnnexon, Inc.2026-08-06 12:00 EST

Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week

TNXPTonix Pharmaceuticals2026-06-29 11:25 EST

Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD)

VTGNVistagen Therapeutics, Inc.2026-08-06 12:30 EST

Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder

TSHATaysha Gene Therapies2026-06-22 12:00 EST

Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome

TEVATeva Pharmaceutical Industries2026-06-18 20:57 EST

Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome

HRMYHarmony Biosciences2026-08-04 11:30 EST

Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile

ANVSAnnovis Bio2026-07-07 11:00 EST

Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease

KTTAPasithea Therapeutics2026-06-16 11:00 EST

Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial

NBIXNeurocrine Biosciences2026-08-12 12:30 EST

Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia

View all latest news

Annexon, Inc.

Classical Complement Inhibition Annexon develops therapies that inhibit the classical complement pathway, which can drive harmful inflammation and tissue damage in neurologic, ophthalmic, and autoimmune diseases. Tanruprubart Tanruprubart is an antibody therapy for Guillain-Barré syndrome. Its European marketing application is under...

Recent company news

ANNXAnnexon, Inc.2026-08-17 20:05 EST

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

ANNXAnnexon, Inc.2026-08-12 10:05 EST

Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones

ANNXAnnexon, Inc.2026-08-12 10:00 EST

Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study

ANNXAnnexon, Inc.2026-08-10 20:05 EST

Annexon Appoints Renowned Retinal Surgeon and Biotechnology Entrepreneur Mark S. Blumenkranz, M.D., M.M.S. to its Board of Directors

ANNXAnnexon, Inc.2026-08-06 12:00 EST

Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week

Stock data

Close
5.07 USD
Market cap
861.81M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States